Table 1.
Patient characteristics
| Overlap syndrome n = 22 | COPD n = 22 | p-value | |
|---|---|---|---|
| Age |
70.0 ± 8.3 |
71.7 ± 8.5 |
0.495 |
| Male, n (%) |
21 (96.7) |
22 (100) |
0.999 |
| BMI |
24.9 ± 3.5 |
22.9 ± 3.0 |
0.054 |
| Smoking, pack-years |
52.3 ± 21.5 |
50.8 ± 26.4 |
0.837 |
| ESS |
12.7 ± 4.5 |
8.3 ± 3.5 |
0.004 |
| PSQ |
11.8 ± 4.0 |
7.5 ± 3.7 |
0.001 |
| Emphysema predominant, n (%) |
5 (22.7) |
14 (63.6) |
0.014 |
|
Pulmonary function test |
|
|
|
| FEV1/FVC |
57.5 ± 12.7 |
54.5 ± 9.6 |
0.197 |
| FEV1 (L) |
1.09 ± 0.51 |
0.95 ± 0.45 |
0.227 |
| FEV1 (% predicted) |
52.7 ± 28.6 |
45.1 ± 19.2 |
0.431 |
| FVC (L) |
1.87 ± 0.69 |
1.70 ± 0.60 |
0.348 |
| FVC (% predicted) |
63.3 ± 25.1 |
57.2 ± 21.7 |
0.378 |
|
Arterial blood gas |
|
|
|
| pH |
7.4 ± 0.0 |
7.4 ± 0.0 |
0.672 |
| PaCO2 (mm Hg) |
41.8 ± 3.8 |
40.6 ± 3.8 |
0.354 |
| PaO2 (mmHg) |
77.5 ± 11.9 |
79.2 ± 9.0 |
0.581 |
|
Medication |
|
|
|
| LABA + ICS, n (%) |
20 (90.9) |
19 (86.4) |
0.565 |
| LAMA, n (%) |
18 (81.8) |
17 (77.3) |
0.907 |
| Theophyllines, n (%) |
6 (27.3) |
2 (9.1) |
0.375 |
|
Comorbidities |
|
|
|
| DM, n (%) |
0 (0) |
1 (4.5) |
- |
| HTN, n (%) |
10 (45.4) |
8 (36.4) |
0.348 |
| CAD, n (%) |
1 (4.5) |
1 (4.5) |
0.823 |
| PAOD, n (%) | 0 (0) | 0 (0) | - |
Data are presented as mean ± SD, or number (percentage).
BMI body mass index, ESS Epworth sleepiness scale, PSQ Pittsburg sleep quality, FEV1 forced expiratory volume in one second, FVC forced volume capacity, ICS inhaled corticosteroids, LABA long-acting β2 agonist, LAMA long-acting muscarinic antagonist, DM diabetes mellitus, HTN hypertension, CAD coronary artery disease, PAOD peripheral arterial occlusion disease.